Glaukos jumps on FDA approval of eye implant

Glaukos

14/12/2023 17:16

** Shares of medtech firm Glaukos Corp  GKOS.N  rise 19.2%
to $72    
    ** Co says the U.S. FDA has approved its drug delivering eye
implant, iDose TR
    ** iDose TR is approved to reduce pressure within the eyes 
in patients with ocular hypertension (OHT) or open-angle
glaucoma (OAG) 
     ** GKOS to begin commercial launch activities for iDose TR
in the latter part of Q1 2024
    ** Glaukos prices iDose TR at a wholesale acquisition cost
of $13,950, per dose or implant
    ** Including session's gain, stock up ~65% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))